Detection of minimal residual disease (MRD) is increasingly used in the management of leukemia patients. A wide variety of methods have been developed and include technologies designed to detect residual malignant cells beyond the sensitivity of conventional approaches such as morphology and banding cytogenetics in leukemia. The choice of the best method depends on the biology of the individual malignancy, i.e. on the determination of specific markers which are useful to differentiate between leukemic cells and normal hematopoiesis in leukemic patients. These markers include leukocyte differentiation antigens, fusion transcripts, transcripts overexpressed by mutated or nonmutated genes, rearranged genes, and individual markers like polymorphic repetitive DNA sequences. The major technologies for MRD detection, their advantages and disadvantages and their clinical applications are discussed in this special issue - from 'bench to bedside'. Providing a comprehensive overview on the significance of MRD in the evaluation, treatment and follow-up of hematologic malignancies, it will be of great value to hematologists, researchers interested in leukemias and lymphomas as well as laboratory technicians.

Master implementation of the techniques of flow cytometry in diagnosing complex haematological diseases and malignancies in patients, worldwide. Featuring World Health Organization recommendations on pre-analytical steps, instrument settings and panel construction, this invaluable manual offers invaluable support for those researching, practising and analyzing the cause of hematological malignancies. Authored by leading experts, this book puts flow-cytometry into everyday context. With a focus on multicolour panels, the manual provides readers an experienced understanding of effective, implementation techniques. Practitioners of all levels are offered a background in a variety of diseases presented alongside the most current methodology. Wide-ranging and comprehensive; detailed images of healthy blood, bone marrow and lymph-nodes are illustrated throughout, allowing for effective diagnosis. Through engaging with differential diagnoses, the manual offers an understanding of similar symptoms and mimicking malignancies, avoiding inaccurate results. Featuring in-depth descriptions of chronic diseases; users can reach accurate diagnosis, first time.

This book provides a state-of-the-art approach to the molecular basis of hematologic diseases and its translation into improved diagnostics and novel therapeutic strategies. Several representative hemato-oncologic malignancies are analyzed in detail: acute lymphoblastic leukemia, acute myeloid leukemia, B-cell Non-Hodgkin lymphomas, multiple myeloma, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Experts in the field describe the molecular methods applied for modern diagnostics and therapies, such as hematopoietic stem cell transplantation, donor recipient matching, banking of biological material, analyses of post-transplant chimerism, and minimal residual disease monitoring. The volume concludes with an extensive section comprising thorough step-by-step protocols of molecular techniques in hematology, all of them validated in the authors’ own laboratories.

Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.

This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.

MDS/MPN With Ring Sideroblasts and Thrombocytosis

This textbook of oncology is aimed at specialist registrars in the early phase of their training. The basic concepts of cancer practice is touched upon in undergraduate and junior postgraduate years, but new trainees frequently seek additional resources to boost their knowledge in the field of Oncology. This title offers a concise account of the multidisciplinary management of common cancers and cancer-related problems appropriate to doctors at the start of their careers in this specialty. The content of the book is based on latest available evidence and reflects the training guidelines. Readable and concise style, aimed at the beginner in this specialty. Well illustrated in colour with graphics, clinical photographs and radiographs. Section on research methodology. Approachable design in the ‘Specialist Training in...’ series style.

Already a standard reference work in the field, the new edition of Blood and Bone Marrow Pathology incorporates the latest WHO classification schemes and the latest ancillary diagnostic techniques in immunohistochemistry and molecular biology in order to provide a comprehensive, well balanced and authoritative guide to the interpretation and diagnosis of neoplastic and non-neoplastic diseases of blood and bone marrow. The text is lavishly illustrated with high quality colour images that demonstrate the relevant pathological,features and immunohistochemical and molecular markers. The text features a well-organized approach that incorporates practical tips and clues to help avoid pitfalls and to ensure optimal diagnosis The book is lavishly illustrated with high quality color images that demonstrate the relevant pathological features and immunohistochemical and molecular markers. The text features a well-organized approach that incorporates practical tips and clues to help avoid pitfalls and to ensure optimal diagnosis. Chapters have been totally rewritten and new chapters have been added, especially on myeloid malignancies. The chapters on hematological malignancies have been written so that the reader can apply the latest WHO Classifications in their routine daily practice (especially the 2008 WHO Classification of Tumors of Hemopoietic and Lymphoid Tissues) All chapters have been revised to include new aspects of molecular biology and flow cytometry diagnostics. Many new schematic diagrams and color illustrations have been added to illustrate blood and bone marrow pathology. Access the full text online and download images via Expert Consult. Chapters have been totally rewritten and some new chapters have been added especially on myeloid malignancies, in line with the WHO 2008 Classification All chapters have been revised to include new aspects of molecular biology and updated concerning flow cytometry diagnostics Greater emphasis on practical diagnostic aspects for all disorders Brand new editorial and contributing author team. Full Online text through Expert Consult. Full downloadable Image Bank Already a standard reference work in the field, the new edition of Blood and Bone Marrow Pathology incorporates the latest WHO classification schemes and the latest ancillary diagnostic techniques in immunohistochemistry and molecular biology in order to provide a comprehensive, well balanced and authoritative guide to the interpretation and diagnosis of neoplastic and non-neoplastic diseases of blood and bone marrow. The text is lavishly illustrated with high quality colour images that demonstrate the relevant pathological,features and immunohistochemical and molecular markers. The text features a well-organized approach that incorporates practical tips and clues to help avoid pitfalls and to ensure optimal diagnosis

This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice.

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.